Aker BioMarine has secured a new contract for the supply of Lysoveta. The
contract value is approximately USD 4 million in 2026, with expected growth in
2027. Gross margin on Lysoveta is significantly higher than for Superba Krill
Oil.
"This is exciting news for Lysoveta, a novel ingredient we have worked on
commercializing over the past years. We believe the potential for Lysoveta is
significant, and we are pleased to see this commercial progress," said Matts
Johansen, CEO of Aker BioMarine.
About Lysoveta
Lysoveta is a krill-derived ingredient from Aker BioMarine, developed through
extensive research. It delivers EPA and DHA in a form that supports transport of
omega-3s to the brain. Lysoveta is intended for use in science-based nutrition
solutions targeting brain health and healthy aging.
For further information, please contact
Christopher Robin Vinter, SVP Finance
Mobile: +47 911 60 820
Email: Christopher.vinter@akerbiomarine.com
This information is considered to be inside information pursuant to the EU
Market Abuse Regulation article 7 and is subject to the disclosure requirements
pursuant to MAR article 17 and Section 5-12 the Norwegian Securities Trading
Act. This stock exchange announcement was published by Christopher Vinter, SVP
Finance, Aker BioMarine ASA, on May 6, 2026, 13:54 CET
About Aker BioMarine
Aker BioMarine is a leading human health and nutrition innovator that develops
krill-derived products for consumer health and nutrition. Krill is a natural,
powerful, and health-promoting source of nutrients from the pristine waters of
Antarctica, and Aker BioMarine has a unique position in its industry. The
ingredient portfolio consists of Superba Krill Oil, Lysoveta, FloraMarine, and
PL+, as well as the consumer brand, Kori Krill. The innovative approach also
extends into the spin-offs AION (reduce and recycle plastic waste across
industries) and Understory (a protein brand). Aker BioMarine is listed on the
Oslo Stock Exchange (AKBM). More information is available at
www.akerbiomarine.com.